Figure 6. IL-13 enhances SARS2-N501YMA30-induced disease in vivo via eicosanoid dysregulation.
8-9 month-old C57BL/6J wild-type (WT) and PLA2G2D-knock-out (KO) mice were pretreated with IL-13 and vehicle for 4 days and infected with 1,000 PFU SARS2-N501YMA30 on day 5. (a) Survival curve of infected wild type and PLA2G2D-knock-out mice. n = 4-5 mice for each group; mean ± SEM; *p<0.05; p value is shown from log-rank (Mantel-Cox) tests for WT Vehicle vs WT IL-13. (b) Viral loads in lungs of infected WT and KO mice on day 2 post infection were assessed by plaque assay. n = lung sample from 3 mice; mean ± SEM; p value is shown from Student's unpaired t test.